Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Radiotherapy for Newly Diagnosed Low-risk NK/T-cell Lymphoma
NCT05477264Phase 2Recruiting
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Extranodal NK/T-cell lymphoma (ENKTL). Primary endpoints: Complete Response Rate up to 51 months and Overall Response Rate up to 51 months. Started Mar 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT05477264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477264.